Prosecution Insights
Last updated: November 18, 2026
Application No. 18/518,341

METHOD, COMPOSITION, AND ARTICLE OF MANUFACTURE FOR PROVIDING ALPHA-1 ANTITRYPSIN

Non-Final OA §103
Filed
Nov 22, 2023
Priority
Nov 02, 2007 — provisional 60/984,975 +3 more
Examiner
GOUGH, TIFFANY MAUREEN
Art Unit
1651
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Grifols Therapeutics LLC
OA Round
3 (Non-Final)
32%
Grant Probability
At Risk
3-4
OA Rounds
78%
With Interview

Examiner Intelligence

Grants only 32% of cases
32%
Career Allowance Rate
166 granted / 523 resolved
-28.3% vs TC avg
Strong +46% interview lift
Without
With
+46.5%
Interview Lift
resolved cases with interview
Typical timeline
Avg Prosecution
38 currently pending
Career history
569
Total Applications
across all art units

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. Applicant’s response filed 3/27/2025 has been received and entered into the case. Claims 1-13 are pending and have been considered on the merits. All arguments and amendments have been considered. *Applicant is advised that should claim 1 be found allowable, claim 13 will be objected to under 37 CFR 1.75 as being a substantial duplicate thereof. When two claims in an application are duplicates or else are so close in content that they both cover the same thing, despite a slight difference in wording, it is proper after allowing one claim to object to the other as being a substantial duplicate of the allowed claim. See MPEP § 608.01(m). Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a). Claims 1, 2, 6-13 are rejected under 35 U.S.C. 103(a) as being unpatentable over Wewers et al. (NE J. of Med, 1987) and Piitulainen in view of WO2005/014648, Barr (US2003/0073217), Shapiro (US7704958 and US6489308). Regarding claims 1, 2, 11, 12, Wewers teach a method of treating alpha-antitrypsin deficiency (AATD) in patients with the PiZZ form of alpha-antitrypsin deficiency according to claim 11 and emphysema according to claim 12, by administering AAT (α1-AT). They teach administration of AAT at a dose which maintains plasma AAT trough levels above the known threshold of 80 mg/dl (abstract, p. 1057, whole page). They teach that a dose of 60 mg/kg body weight administered weekly is demonstrated to increase plasma AAT concentrations to a peak level of above 300 mg/dl which protects against risk for further progression of a disease associated with AAT deficiency (p. 1057, Results section and 1st col. Study design section, Fig. 1). They find that infusing 60 mg/kg body weight over 30 minutes once weekly produces average serum levels of 163 mg/dl which is more than twice the level known to protect against injury by proteases (p.1060, Discussion section, 1st parag., Fig. 1). Wewers, p. 1060, discloses that intravenous infusion of Alpha-1-antitrypsin resulted in a sustained fourfold increase in alph-1- Antitrypsin levels in the lung and a twofold increase in the capacity of the lung to inhibit neutrophil elastase. Regarding claim 8, Wewers teaches a Cmax peak to Cmin trough ratio of about 1.5 after about 72 hours (Fig. 1). Piitulainen teaches a method of treating alpha-antitrypsin deficiency (PiZZ) in emphysema patients by administering AAT (α1-AT). Piitulainen teach subcutaneous IV port administration of AAT (abstract, see entire document) at a dose which maintains plasma AAT trough levels above 70 mg/dl and at least about 80 mg/dl (abstract, p. 153, whole page, Table 3, p.153-155, Results and Discussion section). They teach that a dose of 60 mg/kg body weight administered weekly is demonstrated to increase plasma AAT concentrations to a level of above 70 mg/dl which protects against further progression of a disease associated with AAT deficiency (p.151, last parag.-p.152, 1st parag.) and a dose of 250mg/kg body weight once monthly maintains plasma AAT trough levels above the protective level. They also teach a dosage of 120mg/kg administered every 2 weeks (p. 152, 1st parag.) which maintains trough levels of at least about 80 mg/dl (Table 3). Piitulainen study tailored pharmacokinetic dosing with AAT and a patient’s ability to self-administer (p. 152, 1st col. And whole 2nd col.). They teach that dosage and how often the dosage is administered allows one to maintain protective levels or exceed protective levels until the next infusion (p. 152, whole page, p. 155, 1st col.). Piitulainen teach a therapeutically effective amount sufficient to maintain trough levels of at least 80 mg/dl and administering therapeutically effective amount which maintains trough levels of at least about 80mg/dl. Further, Piitulainen teaches that expected AAT concentration curves in each patient during various dosing schedules were computer-simulated by means of the exponential equation for 4 weeks to find a dosing schedule in which the trough concentrations were predicted to be close to but not less than 70 mg/dl. If the concentrations were found to be less than 70 mg/dl before the last two administrations, new dosing regimens were designed and tried. Given the teachings of the Piitulainen one of ordinary skill in the art would be able to determine a tailored pharmacokinetic dosing regimen for a particular patient having a disorder associated with AAT deficiency and would therefore have a reasonable expectation of success in treating said disorder when administering a therapeutically effective dose which maintains AAT trough levels of at least about 80 mg/dl. It is noted that Piitulainen teaches subcutaneous IV port administration. The above references do not teach subcutaneous administration. WO648 teaches the preparation of an alpha-1-antitrypsin α1-AT solution to be administered subcutaneously and suggests dosages of 60 mg/kg/body weight or 250 mg/kg/ per month (p. 10, first parag.). They teach that those suffering from PiZZ α1-AT deficiencies having emphysema are typically treated with α1-AT solutions (p. 2, whole page). Barr teach administering a therapeutically effective amount of α1-AT to a subject having a disease or disorder associated with α1-AT deficiency, i.e. in respiratory diseases, such as chronic obstructive pulmonary diseases (COPD), cystic fibrosis (CF), asthma, and emphysema (0002-0006, 0010-0014, 0027, 0139). The α1-AT is administered subcutaneously and dosage can be determined which depends on a variety of factors, i.e., “it is understood that the specific dose level for any particular animal subject will depend upon a variety of factors including the activity of the specific compound employed, the age, body weight, general health, gender, and diet of the subject, the time of administration, the route of administration, the rate of excretion, any drug combination, and the degree of expression or activity to be modulated” (0112, 0124, 0129). Shapiro teach administering a therapeutically effective amount of α1-AT to a subject having a disease or disorder associated with α1-AT deficiency (abstract, col. 3, lines 10-55, col.5, lines 1-5, 25-40). The α1-AT is administered subcutaneously (col.5, lines 36-40, col. 9, lines 43-60 for US’958) and (abstract, col. 3, lines 5-32, col. 13,lines 31-67, col.17, lines 30-40, col. 18, lines 6-20 for US’308). Shapiro discloses that AAT easily diffuses into tissue spaces and forms a 1:1 complex with a target protease, principally neutrophil elastase (‘308). Shapiro discloses diseases or disorders for which the therapeutic methods of the invention are beneficial and include but are not limited to asthma, chronic obstructive pulmonary disease. Shapiro discloses that its therapeutic agent may be delivered IV, subcutaneously, or topically (i.e. transdermally), wherein transdermal administration is accomplished by application of a cream, rinse, gel, etc. capable of allowing the inhibitors of serine proteases to penetrate the skin and enter the blood stream” and “parenteral routes of administration include, but are not limited to, direct injection such as intravenous, . . . or subcutaneous injection (see Shapiro ’308 17: 31-36 and 18: 14-19). At the time of the claimed invention, it would have been obvious to one of ordinary skill in the art to pursue known options within his or her technical grasp, i.e. used any route of administration of an AAT formulation disclosed in the art, with a reasonable expectation for successfully treating disease or disorders associated with α1-AT deficiency. AAT is disclosed to be used for subcutaneous administration as well as many other well-known methods. Dosage regimens for maintaining AAT trough levels above the threshold levels are known in the art as is administering AAT at levels which exceed the protective effect. One of ordinary skill in the art would have a reasonable expectation of success in determining the therapeutically effective amount for subcutaneous administration to treat a subject having an AAT deficiency disease because such doses are disclosed by the prior art of record. The prior art references teach amounts falling within applicants claimed 90-200 mg/kg body weight which are administered weekly, bi-weekly or monthly to maintain trough levels of at least about 80 mg/dl. While these amounts are IV doses, these amounts are identified, predictable amounts to treat diseases or disorders associated with α1-AT deficiency, and thus, one has good reason to pursue the known therapeutic amounts for subcutaneous administration with a reasonable expectation of success treating and developing a tailored pharmacokinetic dosing regimen for a particular patient having a disorder associated with AAT deficiency. Regarding claims 6, 7, 9, 10, although the prior art does not specifically disclose these limitations; the Examiner has considered them to be inherent results of the singly claimed method step, i.e., the administration step of the claimed method. Thus, a method of subcutaneously administering the claimed amount would necessarily achieve these results. There is nothing unexpected when administering a known dosage effective to maintain the claimed trough levels at at least about 80mg/dL. Whether the drug is administered via IV or subcutaneous route, the dosages administered via IV to maintain trough levels of at least about 80 mg/dL were known at the time of the claimed invention and the art suggests that the drug can be administered subcutaneously. Providing evidence of what is unexpected when administering subcutaneously versus IV would be beneficial in advancing prosecution since the IV doses and and their effects were known and disclosed by the prior art of record. A comparison of IV versus subcutaneous administration and amount showing unexpected results would be advantageous. It is the Examiners position that WO648, Barr, and Shapiro teach subcutaneous delivery of the claimed drug. Thus, the drug is suggested to be administered via a subcutaneous route. It is the Examiners position that one of ordinary skill in the art would be apprised of how to formulate and administer the drug via well-known routes given the teachings of the prior art and would certainly be apprised of the differences between administration routes and drug absorption. The results provided in applicants examples and Fig. 2 and 4 do not provide any data which is unexpected. When looking to Fig. 1, it is seen that even the same IV and subcutaneous dose are able to maintain a trough level of at least about 80 mg/ml for at least some amount of time. The only results demonstrated in applicants’ figures is that the AUC compared to a single IV dose is lower but does not suggest that one would not have a reasonable expectation of maintaining a trough level as claimed depending on the frequency of administration of a subcutaneous dose. It is the Examiners position that a therapeutically effective amount of the IV dose maintaining trough levels as claimed, could essentially be any amount within the known and disclosed IV ranges to maintain trough levels based upon dosing schedules. The prior art teaches the well-known dosage which achieves a blood trough level as claimed, generally an IV dose of 60-250 mg/kg depending on dosing regimen, i.e., daily, weekly or month is a therapeutically effective amount which maintains blood trough levels about the protective level of 80 mg/dL. Thus, the dosage is optimizable depending on the dosage schedule and individual. Further, subcutaneous administration of α1-AT as well as many other substances, medications etc. is well known and disclosed by the prior art. Subcutaneous administration of compounds is simple and eliminates the need for repeated IV access and is convenient for patients. There is nothing in the prior art which suggests that subcutaneous administration of therapeutic a1-AT would not result in effective delivery to the blood, in fact, the prior art suggests this drug can be administered subcutaneously for treating diseases associated with its deficiency, see Shapiro for example (col. 17, lines 30-35, col. 18, lines 5-30). The art suggests the effective amounts to be administered which would achieve applicants claimed effect, i.e., maintaining trough plasma levels at at least about 80 mg/dl which is consistently known in the art as the level which protects against progression of disorders or diseases associated with α1-AT deficiency (see Piitulainen, for example). The art suggests administration of an amount which is the therapeutically effective amount which maintains these trough levels. Although they are teaching IV administration, the art also teaches subcutaneous administration of the claimed compound. There is nothing which would suggest that a different method of administration would not achieve these same claimed results when administering the same dosage, in addition applicants also discloses different modes of administration may be used. One of skill in the art would only expect that it may be achieved more slowly as IV administration delivers directly to the bloodstream. The question lies in when the peak or trough levels are reached, for how long the administered dosage keeps the plasma levels above trough levels and how often is the dosage administered. When looking to Applicants data, Fig. 4, for example, subcutaneous administration of α1-AT alone is not able to effectively maintain the levels as claimed. It appears to just reach the 80 mg/dl level on day two and decreases thereafter. When administering α1-AT with hyaluronidase, the level is maintained for approximately 2.5 days and then decreases thereafter. It is the Examiners position that if a1-AT is disclosed to maintain the claimed trough levels by administering the claimed therapeutically effective amount and the prior art suggests that modes of administration for such use includes subcutaneous administration then one of ordinary skill in the art would have a reasonable expectation of achieving the discloses and claimed results. Drug administration routes and their delivery to the bloodstream are well within the purview of one of ordinary skill in the art. Further, given that IV trough level maintaining doses are well known in the art, one would adjust subcutaneous doses by routine optimization to maintain art recognized disease treating trough levels. Thus, it would be within the purview of one of ordinary skill in the art to optimize the subcutaneous dose based upon the knowledge of the artisan at the time of the claimed invention. The prior art suggests subcutaneous administration and one of ordinary skill in the art would be apprised of routes of delivery for protein drugs and their method of absorption and bioavailability. Further, given that IV trough level maintaining doses are well known in the art, one would adjust subcutaneous doses by routine optimization to maintain art recognized disease treating trough levels. At the time of the claimed invention, IV doses known to maintain the trough levels as claimed were taught by the prior art and one would have a reasonable expectation of successfully achieving and maintaining said trough levels when administering the same known therapeutically effective doses via the finite number of disclosed administration routes for the claimed drug, i.e., subcutaneously. The obvious to try rational applies, i.e. “At the time of the claimed invention, it would have been obvious to one of ordinary skill in the art to pursue known options within his or her technical grasp, i.e. used any route of administration of an AAT formulation disclosed in the art, with a reasonable expectation for successfully treating disease or disorders associated with α1-AT deficiency” and it would have been obvious to administer the drug by methods which were suggested by the art because there were a finite number of modes of administration. Further, given the “inconveniences” recognized with IV administration it would have been reasonable to pursue potential solutions with an expectation of success. There is nothing in the art to suggest that the effective IV doses could not be administered subcutaneous to achieve the same outcome. Thus, it would be obvious, based on the combined prior art references, to optimize the concentration of AAT administered subcutaneously to, at least, achieve the art recognized effective blood trough levels of about 80 mg/dl. of above 80 mg/dL. “Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456 (CCPA 1955). Claims 3-5 are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Wewers et al. (NE J. of Med, 1987) and Piitulainen in view of WO2005/014648, Barr (US2003/0073217), Shapiro (US7704958 and US6489308), as applied to claims 1, 2, 6-13 above, and further in view of Bookbinder et al. (US20060104968) and Favre et al. (Gene Therapy, 2000). The teachings of ewers et al. (NE J. of Med, 1987) and Piitulainen in view of WO648, Barr (US2003/0073217), Shapiro (US7704958), Shapiro (US6489308) are found above. Regarding claim 3, the references do not teach α1-AT administered in combination with a hyaluronidase. Bookbinder teaches administering hyaluronidase with other molecules to alleviate pathologies (Abstract, 0158, 0379). Bookbinder teaches co-administration or co-formulation of hyaluronidase with alpha-1-proteinase inhibitor (0450). They teach lyophilized formulations (0050, 0491-0495). They teach that subcutaneous administration of molecules with hyaluronidase facilitates their systemic distribution more rapidly (0054, 0059, 0073, 0458) and promotes dispersion (0066, 0068, 0069, 0070). Favre teach that administering hyaluronidase prior to vector injection resulted in larger diffusion of the virus and a two or three-fold increase of transduction efficiency measured by the number of positive fibers or by the hAAT concentration (abstract, p. 418, whole page). They used a rAAV vector harboring the human α1-AT(hAAT) cDNA. The hAAT protein is expressed and secreted from the myofibers and measured in serum therefore making it a marker to test rAAV transduction. After rAAVhAAT vector administration, circulating hAAT was three-fold higher in the hyaluronidase treated animal (p. 418, last paragraph). Therefore, hyaluronidase administration increases intramuscular diffusion and enhances transduction two-three-fold. It would have been obvious to one of ordinary skill in the art to administer hyaluronidase with AAT with a reasonable expectation for successful subcutaneous administration because the art teaches that hyaluronidase in combination with therapeutic molecules facilitates their systemic distribution more rapidly and promotes dispersion of the molecule as well as enhancing AAT circulation by three-fold. Thus, all the claimed elements were known in the prior art and one skilled in the art could have combined the elements as claimed by known methods with no change in their respective functions and the combination would have yielded predictable results to one of ordinary skill in the art at the time of the invention. Regarding claims 4, 5, although the prior art does not specifically disclose these limitations; the Examiner has considered them to be inherent results of the singly claimed method step, i.e., the administration step of the claimed method. Thus, a method of subcutaneously administering the claimed amount would necessarily achieve these results. Response to Arguments Applicant's arguments filed 3/27/2025 have been fully considered but they are not persuasive. Applicants argue that neither Wewers and Piitulainen teach subcutaneous administration and the secondary references (WO648) suggests dosages of 60 mg/kg or 250 mg/kg, which are outside of applicants claimed range, while Barr and Shapiro refer to therapeutically effective amounts without suggesting a particular range. Applicants argue that determining a subcutaneous dose based on the lack of guidance from the references is entirely unpredictable, and cite a review article by Bittner et al. entitled “Subcutaneous Administration of Biotherapeutics: An Overview of Current Challenges and Opportunities, citing “Potential differences in the safety, immunogenicity, and efficacy of subcutaneous versus intravenous administration are best visualized by comparing the pharmacokinetic profiles of a therapeutic protein that can be administered via either route. A biotherapeutic intravenous infusion or injection directly into the bloodstream usually results in immediate maximum serum concentrations (Cmax), whereas the pharmacokinetic profile of subcutaneously injected therapeutic proteins is typically characterized by a slow absorption rate from the subcutaneous extracellular matrix with Cmax levels below those achieved with intravenous dosing”. Applicant argues that therefore, a posita would have no basis to determine the recited dosage range for subcutaneous administration with any reasonable expectation of success. The teachings of Bittner have been considered but Bittner teaches “Generally, when developing a subcutaneous dosing alternative for a molecule that is already on the market…with an IV bodyweight or body surface area-adjusted regimen, a change to a fixed dose or dose band for predefined weight categories could be considered.” The reference also teaches that when developing subcutaneous formulations…, the change from IV to subcutaneous included a switch from weight-and body surface area-adjusted dosing to a fixed dose…based on pharmacokinetic bridging approach assuming that subcutaneous dose achieving serum trough concentrations non-inferior to hose with IV dosing would achieve… comparable efficacy.” Therefore, Bittner supports the Examiners position that one of ordinary skill in the art would be apprised of how to formulate and administer the drug via well-known routes given the teachings of the prior art and would certainly be apprised of the differences between administration routes and drug absorption. The results provided in applicants examples and Fig. 2 and 4 do not provide any data which is unexpected. When looking to Fig. 1, it is seen that even the same IV and subcutaneous dose are able to maintain a trough level of at least about 80 mg/ml for at least some amount of time. The only results demonstrated in applicants’ figures is that the AUC compared to a single IV dose is lower but does not suggest that one would not have a reasonable expectation of maintaining a trough level as claimed depending on the frequency of administration of a subcutaneous dose. It is the Examiners position that a therapeutically effective amount of the IV dose maintaining trough levels as claimed, could essentially be any amount within the known and disclosed IV ranges to maintain trough levels based upon dosing schedules. The prior art teaches the well-known dosage which achieves a blood trough level as claimed, generally an IV dose of 60-250 mg/kg depending on dosing regimen, i.e., daily, weekly or month is a therapeutically effective amount which maintains blood trough levels about the protective level of 80 mg/dL. Thus, the dosage is optimizable depending on the dosage schedule and individual. Further, subcutaneous administration of α1-AT as well as many other substances, medications etc. is well known and disclosed by the prior art. Subcutaneous administration of compounds is simple and eliminates the need for repeated IV access and is convenient for patients. There is nothing in the prior art which suggests that subcutaneous administration of therapeutic a1-AT would not result in effective delivery to the blood, in fact, the prior art suggests this drug can be administered subcutaneously for treating diseases associated with its deficiency, see Shapiro for example (col. 17, lines 30-35, col. 18, lines 5-30). The art suggests the effective amounts to be administered which would achieve applicants claimed effect, i.e., maintaining trough plasma levels at at least about 80 mg/dl which is consistently known in the art as the level which protects against progression of disorders or diseases associated with α1-AT deficiency (see Piitulainen, for example). The art suggests administration of an amount which is the therapeutically effective amount which maintains these trough levels. Although they are teaching IV administration, the art also teaches subcutaneous administration of the claimed compound. There is nothing which would suggest that a different method of administration would not achieve these same claimed results when administering the same dosage, in addition applicants also discloses different modes of administration may be used. One of skill in the art would only expect that it may be achieved more slowly as IV administration delivers directly to the bloodstream. The question lies in when the peak or trough levels are reached, for how long the administered dosage keeps the plasma levels above trough levels and how often is the dosage administered. When looking to Applicants data, Fig. 4, for example, subcutaneous administration of α1-AT alone is not able to effectively maintain the levels as claimed. It appears to just reach the 80 mg/dl level on day two and decreases thereafter. When administering α1-AT with hyaluronidase, the level is maintained for approximately 2.5 days and then decreases thereafter. It is the Examiners position that if a1-AT is disclosed to maintain the claimed trough levels by administering the claimed therapeutically effective amount and the prior art suggests that modes of administration for such use includes subcutaneous administration then one of ordinary skill in the art would have a reasonable expectation of achieving the discloses and claimed results. Drug administration routes and their delivery to the bloodstream are well within the purview of one of ordinary skill in the art. Further, given that IV trough level maintaining doses are well known in the art, one would adjust subcutaneous doses by routine optimization to maintain art recognized disease treating trough levels. Thus, it would be within the purview of one of ordinary skill in the art to optimize the subcutaneous dose based upon the knowledge of the artisan at the time of the claimed invention. The prior art suggests subcutaneous administration and one of ordinary skill in the art would be apprised of routes of delivery for protein drugs and their method of absorption and bioavailability. Further, given that IV trough level maintaining doses are well known in the art, one would adjust subcutaneous doses by routine optimization to maintain art recognized disease treating trough levels. At the time of the claimed invention, IV doses known to maintain the trough levels as claimed were taught by the prior art and one would have a reasonable expectation of successfully achieving and maintaining said trough levels when administering the same known therapeutically effective doses via the finite number of disclosed administration routes for the claimed drug, i.e., subcutaneously. The obvious to try rational applies, i.e. “At the time of the claimed invention, it would have been obvious to one of ordinary skill in the art to pursue known options within his or her technical grasp, i.e. used any route of administration of an AAT formulation disclosed in the art, with a reasonable expectation for successfully treating disease or disorders associated with α1-AT deficiency” and it would have been obvious to administer the drug by methods which were suggested by the art because there were a finite number of modes of administration. Further, given the “inconveniences” recognized with IV administration it would have been reasonable to pursue potential solutions with an expectation of success. There is nothing in the art to suggest that the effective IV doses could not be administered subcutaneous to achieve the same outcome. Thus, it would be obvious, based on the combined prior art references, to optimize the concentration of AAT administered subcutaneously to, at least, achieve the art recognized effective blood trough levels of about 80 mg/dl. of above 80 mg/dL. “Where the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation.” In re Aller, 220 F.2d 454, 456 (CCPA 1955). Dosage regimens for maintaining AAT trough levels above the threshold levels are known in the art as is administering AAT at levels which exceed the protective effect. One of ordinary skill in the art would have a reasonable expectation of success in determining the therapeutically effective amount for subcutaneous administration to treat a subject having an AAT deficiency disease because such doses are disclosed by the prior art of record. The prior art references teach amounts falling within applicants claimed 90-200 mg/kg body weight which are administered weekly, bi-weekly or monthly to maintain trough levels of at least about 80 mg/dl. While these amounts are IV doses, these amounts are identified, predictable amounts to treat diseases or disorders associated with α1-AT deficiency, and thus, one has good reason to pursue the known therapeutic amounts for subcutaneous administration with a reasonable expectation of success treating and developing a tailored pharmacokinetic dosing regimen for a particular patient having a disorder associated with AAT deficiency. Conclusion THIS ACTION IS MADE FINAL. Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a). A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not mailed until after the end of the THREE-MONTH shortened statutory period, then the shortened statutory period will expire on the date the advisory action is mailed, and any nonprovisional extension fee (37 CFR 1.17(a)) pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action. Any inquiry concerning this communication or earlier communications from the examiner should be directed to TIFFANY MAUREEN GOUGH whose telephone number is (571)272-0697. The examiner can normally be reached M-Thu 8-5. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Adam Weidner can be reached at 571-272-3045. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TIFFANY M GOUGH/Examiner, Art Unit 1651 /Adam Weidner/SPE, Art Unit 1651
Read full office action

Prosecution Timeline

Show 1 earlier event
Sep 27, 2024
Non-Final Rejection mailed — §103
Mar 27, 2025
Response Filed
Jun 25, 2025
Final Rejection mailed — §103
Dec 23, 2025
Notice of Allowance
Jul 21, 2026
Request for Continued Examination
Jul 21, 2026
Response after Non-Final Action
Jul 22, 2026
Response after Non-Final Action
Nov 17, 2026
Non-Final Rejection mailed — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12778995
METHOD OF USING A COMBINATION OF POSTBIOTICS AND PROBIOTICS FOR PREVENTION OF SEVERE ACUTE RESPIRATORY SYNDROME CORONAVIRUS 2 INFECTION-ASSOCIATED DISORDERS
3y 0m to grant Granted Nov 03, 2026
Patent 12758600
Systems, Methods, and Compositions for Treating or Preventing Bacterial Infection and for Reducing or Preventing Bacterial Overpopulation
5y 9m to grant Granted Oct 13, 2026
Patent 12642821
USE OF AKKERMANSIA FOR TREATING METABOLIC DISORDERS
1y 0m to grant Granted Jun 02, 2026
Patent 12584113
METHOD OF CELL CULTURE
6y 3m to grant Granted Mar 24, 2026
Patent 12576138
COMPOUNDS AND METHODS FOR THE IMMOBILIZATION OF MYOSTATIN-INHIBITORS ON THE EXTRACELLULAR MATRIX BY TRANSGLUTAMINASE
5y 5m to grant Granted Mar 17, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
32%
Grant Probability
78%
With Interview (+46.5%)
High
PTA Risk
Based on 523 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month